Free Trial
NASDAQ:SNTI

Senti Biosciences (SNTI) Stock Price, News & Analysis

Senti Biosciences logo
$1.40 +0.01 (+0.72%)
As of 01:17 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Senti Biosciences Stock (NASDAQ:SNTI)

Advanced

Key Stats

Today's Range
$1.38
$1.42
50-Day Range
$1.30
$2.35
52-Week Range
$1.26
$16.94
Volume
20,775 shs
Average Volume
169,231 shs
Market Capitalization
$36.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Buy

Company Overview

Senti Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

SNTI MarketRank™: 

Senti Biosciences scored higher than 68% of companies evaluated by MarketBeat, and ranked 350th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Senti Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Senti Biosciences has a consensus price target of $8.50, representing about 507.1% upside from its current price of $1.40.

  • Amount of Analyst Coverage

    Senti Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Senti Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Senti Biosciences are expected to grow in the coming year, from ($14.54) to ($1.88) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Senti Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Senti Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Senti Biosciences has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Senti Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    3.02% of the float of Senti Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Senti Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Senti Biosciences has recently decreased by 21.68%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Senti Biosciences does not currently pay a dividend.

  • Dividend Growth

    Senti Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.02% of the float of Senti Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Senti Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Senti Biosciences has recently decreased by 21.68%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Senti Biosciences has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Senti Biosciences this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for SNTI on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Senti Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Senti Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.12% of the stock of Senti Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 25.73% of the stock of Senti Biosciences is held by institutions.

  • Read more about Senti Biosciences' insider trading history.
Receive SNTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SNTI Stock News Headlines

Alert: Prepare for Trump's Dollar Overhaul
President Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."tc pixel
See More Headlines

SNTI Stock Analysis - Frequently Asked Questions

Senti Biosciences' stock was trading at $3.51 at the beginning of 2025. Since then, SNTI shares have decreased by 60.1% and is now trading at $1.40.

Senti Biosciences, Inc. (NASDAQ:SNTI) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.58) by $0.02. The business earned $0.50 million during the quarter, compared to the consensus estimate of $1.30 million.

Shares of Senti Biosciences reverse split before market open on Thursday, July 18th 2024.The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Senti Biosciences' top institutional shareholders include Armistice Capital LLC (3.41%) and Geode Capital Management LLC (0.56%).
View institutional ownership trends
.

Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Senti Biosciences investors own include NVIDIA (NVDA), PayPal (PYPL), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Coinbase Global (COIN) and SoFi Technologies (SOFI).

Company Calendar

Last Earnings
8/07/2025
Today
9/17/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SNTI
CIK
1854270
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$5.00
Potential Upside/Downside
+515.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($8.95)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$52.79 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-223.98%
Return on Assets
-76.02%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.26
Quick Ratio
3.26

Sales & Book Value

Annual Sales
$2.56 million
Price / Sales
14.11
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.31 per share
Price / Book
0.26

Miscellaneous

Outstanding Shares
26,160,000
Free Float
25,344,000
Market Cap
$36.13 million
Optionable
Not Optionable
Beta
2.06

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:SNTI) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners